Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab

Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus (DM) and is characterized by hyperglycemia, hyperketonemia and metabolic acidosis. With the increasing use of immune checkpoint inhibitors (ICIs), such as pembrolizumab in cancer therapy, it’s important tounderstand immune-related adverse events that comes with it